📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 19:21
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Johnson Pharmacare Q1 Results: Auditor flags non-compliance with Ind AS standards
Johnson Pharmacare submitted its un-audited financial results for the quarter ended June 30, 2026. The statutory auditor, VRSK & Associates, issued a significant observation stating that the results were not prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act. This is critical given the company's existing financial distress, including a TTM revenue of Rs 0 Cr and a net worth of Rs 0 Cr.
Confidence: HIGH
What changedThe company has filed its Q1 FY27 results, which have been met with a modified auditor's report regarding accounting standard violations.
Why it mattersThe auditor's emphasis on non-compliance with Ind AS, combined with zero revenue and zero net worth, suggests significant governance and going-concern risks.
Market Cap: Rs 27 CrTTM Revenue: Rs 0 CrDebt: Rs 21 CrNet Worth: Rs 0 CrTTM PAT: Rs -56 Cr
📅 Short termThe stock is likely to face pressure due to the auditor's negative remarks on accounting compliance and the continued absence of revenue.
📈 Long termThe long-term outlook is highly uncertain given the lack of a functional business model (zero revenue) and negative equity position.
⚠ Risk flags
- Non-compliance with Ind AS accounting standards
- Zero operational revenue
- Zero net worth
- High debt-to-market cap ratio
Key Highlights
Statutory auditor noted that financial results were not prepared in accordance with Ind AS standards
Company reported TTM revenue of Rs 0 Cr and a TTM net loss of Rs 56 Cr
Debt stands at Rs 21 Cr against a market capitalization of only Rs 27 Cr
Net worth is currently reported at Rs 0 Cr, indicating severe financial instability
Board meeting for result approval concluded at 05:30 P.M. on August 13, 2026
👀 What to Watch
Investors should exercise extreme caution and monitor for any subsequent filings that address the auditor's concerns regarding Ind AS non-compliance and the lack of operational revenue.
Johnson Pharmacare Approves Q1 FY27 Results; Auditor Notes Ind AS Non-Compliance
Johnson Pharmacare approved its un-audited financial results for the quarter ended June 30, 2026. The company continues to operate in a distressed financial state, with TTM revenue at Rs 0 Cr and a massive FY26 net loss of Rs 56 Cr, which exceeds its current market capitalization of Rs 27 Cr. Notably, the statutory auditor's limited review report stated that the results were not prepared in accordance with Ind AS standards. The company also confirmed no funds were raised through public or preferential issues during the quarter.
Confidence: HIGH
What changedThe company has released its first-quarter financial results for the 2026-27 fiscal year, maintaining its status as a non-operational entity with significant losses.
Why it mattersThe combination of zero revenue, negative net worth, and auditor qualifications regarding accounting standards indicates severe fundamental weakness and high risk for shareholders.
Market Cap: Rs 27 CrTTM Revenue: Rs 0 CrFY26 Net Loss: Rs 56 CrDebt: Rs 21 CrLoss vs Market Cap: 207.4%
📅 Short termThe stock is likely to remain under pressure due to the lack of operational progress and the auditor's negative observation on accounting standards.
📈 Long termThe long-term outlook is highly uncertain given the lack of a revenue-generating business model and a depleted net worth.
⚠ Risk flags
- Zero operational revenue
- Auditor qualification on Ind AS non-compliance
- Negative net worth
- High debt relative to zero revenue
Key Highlights
Board approved un-audited financial results for the quarter ended June 30, 2026
Statutory auditor VRSK & Associates noted results were not prepared in accordance with Ind AS under Section 133 of the Companies Act
Company reported zero revenue (Rs 0 Cr) for the entire TTM period ending March 2026
FY26 net loss of Rs 56 Cr is significantly higher than the company's total market cap of Rs 27 Cr
Net worth remains at Rs 0 Cr with a debt burden of Rs 21 Cr as per latest financial context
👀 What to Watch
Investors should exercise extreme caution and monitor if the company can restart revenue operations or address the auditor's concerns regarding Ind AS compliance.
